Mitigation of QingLuoTongMai Pills on Chemotherapy-induced Phlebitis: A Network Pharmacology Study and Experimental Validation.

OBJECTIVE

Chemotherapy-induced phlebitis (CIP) is a side product of chemotherapy treatment for malignant tumors, which affects the therapeutic effect and quality of life of cancer patients, and still lacks a clear therapeutic means. In this study, we investigated the therapeutic effects of QLTMP on CIP using network pharmacology and verified the anti-inflammatory mechanism of QLTMP in a mice model induced by vinorelbine.

METHODS

Network pharmacology analysis was performed to identify bioactive compounds in QLTMP. The protein-protein interaction network was used to identify the core therapeutic targets of QLTMP against CIP, analyze biological function and pathway enrichment based on the identified core therapeutic targets, and evaluate the therapeutic effect of QLTMP in a model of CIP induced by vinorelbine to confirm the reliability of the network pharmacological analysis. One hundred and sixty-five bioactive compounds of QLTMP matched the screening criteria and identified 19 core therapeutic targets of QLTMP against CIP. Biofunctional analysis showed that the therapeutic effect of QLTMP on CIP was mainly related to the inhibition of inflammation, while pathway enrichment analysis showed that the TNF signaling pathway was involved in the inflammatory process.

RESULTS

Experimental confirmation in a mice model showed that QLTMP exerts anti-inflammatory effects through modulation of the PI3K/AKT/TNF signaling pathway, a discovery consistent with the network pharmacological analysis.

DISCUSSION AND

CONCLUSION

The network pharmacological analysis of the anti-inflammatory mechanism of QLTMP on CIP and its exploration of in vivo experiments provide a theoretical basis for the design of agents that can mitigate or cure CIP.